MedTrace Logo

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

NCT03804593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2020-01-30

No results posted yet for this study

Summary

This is a multi-center study to prospectively gather clinically-characterized plasma samples to determine the diagnostic performance characteristics (sensitivity and specificity) of the HCCBloodTest among patients with cirrhosis with and without HCC

Conditions

Sponsors & Collaborators

  • Innovis LLC

    collaborator INDUSTRY

  • Epigenomics, Inc

    lead INDUSTRY

Principal Investigators

  • Theo DeVos · Epigenomics, Inc

  • Nick Potter · Epigenomics, Inc

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2019-10-01
Completion
2019-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804593 on ClinicalTrials.gov